Kewaunee reports lower sales. Kewaunee Scientific stock sits 27.38 percent below its high

Published on 10/06/2026 at 01:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fiscal 2027 first-quarter net earnings fell 44.80 percent to USD 1.71 million. Kewaunee Scientific stock is valued at USD 97.0 million.

KEQU, US4928541048, Illustration mit AI erstellt.

Kewaunee Scientific stock sits 27.38 percent below its USD 46.57 52-week high after the company reported lower fiscal 2027 first-quarter sales on September 9, 2026. According to PR Newswire, sales fell 6.70 percent year over year to USD 66.32 million for the quarter ended July 31, 2026.

Sales and earnings move lower

Net earnings attributable to Kewaunee Scientific fell to USD 1.71 million from USD 3.09 million in the prior-year quarter, a decline of 44.80 percent. Diluted earnings per share dropped to USD 0.58 from USD 1.04, while pre-tax earnings declined 34.70 percent to USD 2.56 million.

The operating picture was mixed. Consolidated non-GAAP EBITDA fell to USD 4.53 million from USD 6.32 million, reflecting lower manufacturing volumes and higher corporate compensation expense tied to awards settled in cash rather than shares.

Backlog offers a counterpoint

Order backlog increased to USD 169.0 million on July 31, 2026, from USD 165.9 million on April 30, 2026. The sequential improvement provides a measurable counterpoint to the year-over-year sales decline, although the backlog remained below USD 205.0 million a year earlier.

International operations supplied the strongest comparison in the quarter. International segment net earnings rose 23.50 percent to USD 0.79 million, while segment EBITDA increased 13.90 percent to USD 1.20 million, supported by a higher-margin project mix. Lab Products Group sales fell 6.40 percent to USD 50.87 million, while segment EBITDA reached USD 6.59 million.

According to the SEC filing dated September 9, 2026, Kewaunee Scientific trades under ticker KEQU on the Nasdaq Global Market. The filing identifies the results as the companys first-quarter fiscal 2027 report.

Stock remains below yearly high

KEQU had a market capitalization of USD 97.0 million as of October 5, 2026. Its 52-week range was USD 32.00 to USD 46.57, placing the USD 33.82 primary-market quote 27.38 percent below the high and 5.69 percent above the low.

For investors, the central tension is clear: backlog and international profitability improved sequentially, while consolidated sales, earnings and diluted earnings per share weakened year over year. Kewaunee also reported long-term debt excluding its sale-leaseback financing obligation of USD 13.84 million on July 31, 2026, compared with USD 15.09 million on April 30, 2026.

Quarterly results define the setup

The next market assessment will depend on whether backlog converts into project releases and whether international margins remain supportive. Kewaunee said project award and release timelines were extended by broader geopolitical and economic uncertainty in its September 9, 2026 release.